Journal
JOURNAL OF VIROLOGY
Volume 84, Issue 18, Pages 9632-9636Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.00451-10
Keywords
-
Categories
Funding
- National Institutes of Health [5RO1AI06275-03]
- U.S. Department of Energy
- CDC
- Georgia Research Alliance
Ask authors/readers for more resources
We examined whether prophylactically administered anti-respiratory syncytial virus (anti-RSV) G monoclonal antibody (MAb) would decrease the pulmonary inflammation associated with primary RSV infection and formalin-inactivated RSV (FI-RSV)-enhanced disease in mice. MAb 131-2G administration 1 day prior to primary infection reduced the pulmonary inflammatory response and the level of RSV replication. Further, intact or F(ab')(2) forms of MAb 131-2G administered 1 day prior to infection in FI-RSV-vaccinated mice reduced enhanced inflammation and disease. This study shows that an anti-RSV G protein MAb might provide prophylaxis against both primary infection and FI-RSV-associated enhanced disease. It is possible that antibodies with similar reactivities might prevent enhanced disease and improve the safety of nonlive virus vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available